Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800752 | 0.78 | ACACB (0.38) | TSHRPOLBACACBCRHR1PLAU | |
| SCHEMBL31280071 | 0.72 | TSHR (0.45) | TSHRPOLBCDC7DBF4ACACB | |
| SCHEMBL4805217 | 0.72 | DGAT1 (0.37) | POLBSMN1; SMN2TDP1CYP1A2CYP2C9 | |
| SCHEMBL19355446 | 0.72 | CRHR1 (0.43) | TSHRACACBCRHR1PLAUCYP1A2 | |
| SCHEMBL2611028 | 0.71 | PIK3CA (0.39) | ACACBALDH1A1SMN1; SMN2CRHR1PLAU | |
| SCHEMBL2292326 | 0.71 | ALDH1A1 (0.34) | TSHRPOLBALDH1A1CTSKSMN1; SMN2 | |
| SCHEMBL29180861 | 0.70 | MAPT (0.45) | POLBALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL12044436 | 0.70 | CRHR1 (0.43) | TSHRACACBHSD17B10ALDH1A1CRHR1 | |
| SCHEMBL11597406 | 0.68 | HSP90AA1 (0.47) | TSHRALDH1A1SMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL24094774 | 0.68 | NNMT (0.40) | TSHRPOLBACACBALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | ZHANG XUQING | 2008-09-11 | — | — | US | disclosed |
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | ZHANG XUQING | 2008-09-11 | — | — | US | disclosed |
| US-7399767-B2 | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399767-B2 | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| CN-101146798-A | Novel heterocyclic benzo[C]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-19 | — | — | CN | disclosed |
| EP-1846397-A1 | NOVEL HETEROCYCLIC BENZOY[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| US-20060205741-A1 | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006078834-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205741-A1 | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | GPER1, ESR1, ESR2 | TSHR 156/4885POLB 3573/4885CDC7 1834/4885 |
| US-20080221125-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | GPER1, ESR1, ESR2 | TSHR 156/4885POLB 3573/4885CDC7 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.